RalGDS is required for tumor formation in a model of skin carcinogenesis.
about
Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growthDisruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsTuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPasesActivation of the RalGEF/Ral pathway promotes prostate cancer metastasis to boneTumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RASRas superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Ral GTPases: crucial mediators of exocytosis and tumourigenesisRal GTPases in tumorigenesis: emerging from the shadowsAberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanismsRalB mobilizes the exocyst to drive cell migrationBRAF mutation predicts sensitivity to MEK inhibitionRas oncogenes: split personalitiesRas history: The saga continues.The Ral/exocyst effector complex counters c-Jun N-terminal kinase-dependent apoptosis in Drosophila melanogaster.R-Ras regulates exocytosis by Rgl2/Rlf-mediated activation of RalA on endosomes.Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by RasKRAS and YAP1 converge to regulate EMT and tumor survivalRal activation promotes melanomagenesis.RAS Interaction with PI3K: More Than Just Another Effector PathwayRal small GTPase signaling and oncogenesis: More than just 15minutes of fameThe chromosomal instability pathway in colon cancerTargeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformationLoss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis.The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.mTOR-independent translational control of the extrinsic cell death pathway by RalA.Drugging the undruggable RAS: Mission possible?RalA functions as an indispensable signal mediator for the nutrient-sensing systemThe anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras.M-Ras induces Ral and JNK activation to regulate MEK/ERK-independent gene expression in MCF-7 breast cancer cells.Inhibition of Ras for cancer treatment: the search continues.IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesisEndocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells.RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics.The genetics and biology of KRAS in lung cancer.Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.Tumor suppressor role of phospholipase C epsilon in Ras-triggered cancers.Ras and Raf pathways in epidermis development and carcinogenesis.
P2860
Q24294230-F9FBE2F9-B4F6-4C2E-97EF-9700D0194397Q24294914-F9B7DB77-61BF-452B-9433-7445F6E62000Q24337797-76543F84-797B-428E-B62A-11B57115A980Q24681479-9EFBA322-3B57-43F8-9899-F41F5603503FQ27645826-3D1AFC24-7FB9-4026-BCCB-FB6B8537E95EQ27690752-BDDF2F99-89CE-4BFE-8FF5-DC978EBFEB83Q28259292-8F1C920A-1787-4FB9-8A47-C2FF7DC2E3DFQ28294053-25D96FE0-658C-4E09-AC1D-A4E81C5B7FDEQ28384212-F58076FE-DAF3-4847-B721-6B4ECE30A4CCQ28570438-13F28B36-60C4-4714-BA26-4DC5BA4172A2Q29614281-4E6C7F4D-1EE2-4479-B80C-03E7A83F0823Q29615405-BB2D35E2-1B89-4941-98FE-3732AF8897EAQ30404024-787377DC-D882-4010-BC49-2F8D231D63FEQ30478286-677F9A5F-1749-473A-AC78-F63D27DCE7F1Q30479311-8AAF75EC-1285-4605-8058-FDF19235508FQ33241589-F61AF200-17D5-4FC1-9692-13E376A21FD6Q33946244-4F39DEED-7604-41AA-A1B7-30E9744C1182Q34086528-D91A1B0F-711D-4604-8AEF-E1E53764A7EFQ34202692-EB2521D6-1378-492E-BDB4-CD20E0FB5E07Q34363605-B2018546-DA27-4581-8139-05DCFE7F8433Q34570062-C6505609-BA74-4034-B0BB-D138EEB74DBEQ34659415-E8D9708A-4FF6-465B-8AA9-C5E43F995255Q34887145-CCEF2E33-DD6B-4776-8C4C-E890748BE57DQ35060981-714453AB-C9A4-40A4-B564-776EBE7618A1Q35064340-F46620B2-6F2A-4BCC-8453-216B6E6E9565Q35083727-8410A9ED-7B9F-4DF3-BD02-83D8797CD707Q35131738-78E6654B-D89A-4670-8F12-246F8E48C28DQ35163434-0C13E4FD-2D03-463B-89CC-28DC0C59D764Q35676903-25B80137-6B7C-41D8-BE36-0923E671A590Q35823298-979D25E7-EAE7-4D14-B221-0857AC162AD8Q35830796-C9A26D91-0AD9-4E48-917F-FD2A0881D4DBQ35944601-8C68C56D-7E81-4DC5-8945-AD59287E61C8Q36193541-E551FA40-286A-4695-91DF-7C6D1C29087AQ36926955-6D86CE96-A607-47D7-8154-2F1935D0CDC5Q37048053-319A0753-27FA-4DEB-B1F0-53CB21E41B27Q37072842-4068A666-8563-4F5E-AE88-D3536032E204Q37354111-93B5D92A-1130-4B8E-87F3-05AE1DA27A03Q37564511-25BE0B8C-BC8B-408E-A9E3-CFC6CCB4AF62Q37660073-5829B402-4D9B-470E-9160-7FE708E9CB3FQ37809957-AA946DBF-B6D8-42B1-9DCF-6B0C8B62B526
P2860
RalGDS is required for tumor formation in a model of skin carcinogenesis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
RalGDS is required for tumor formation in a model of skin carcinogenesis.
@en
type
label
RalGDS is required for tumor formation in a model of skin carcinogenesis.
@en
prefLabel
RalGDS is required for tumor formation in a model of skin carcinogenesis.
@en
P2093
P1433
P1476
RalGDS is required for tumor formation in a model of skin carcinogenesis
@en
P2093
Ana González-García
Christopher J Marshall
Georgia Mavria
Gordon Stamp
Hugh F Paterson
P304
P356
10.1016/J.CCR.2005.01.029
P577
2005-03-01T00:00:00Z